Pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted, GlaxoSmithKline)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NamePandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted, GlaxoSmithKline)
Drug Alias NameH5N1裂解灭活病毒佐剂疫苗Q-Pan H5N1Influenza A virus vaccine H5N1Split virion, inactivated, adjuvanted (pre-)pandemic H5N1 influenza vaccine(Pre)-pandemic vaccine against H5N1 inactivated split - monovalent +[7] 
ClassificationVaccines > Development/production technology > Inactivated vaccine > Split vaccineVaccines > Application > Prophylactic vaccineVaccines > Biological material > Viral vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsInfluenza A virus infectionsInfluenza, Human
Global Approved IndicationsInfluenza, Human
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2009/10/10
Country/TerritoryBelgiumUnited StatesEU
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesGlaxosmithkline Biologicals SA
Inactive CompaniesGlaxosmithkline PlcNational Institute Of Allergy And Infectious Diseases (Niaid)
Active IndicationsInfluenza, Human
Inactive IndicationsInfluenza A virus infections

Other Information

ATC CodeJ07BB02
Related LinksWikipedia